Novartis published trial results showing its drug succeeded in tackling difficult to treat breast cancer with PIK3CA mutation, after other pharma giants including Roche failed and abandoned ...

If the deal goes through, Scorpion will spin its non-PI3K pipeline assets – which include a pair of EGFR inhibitors codenamed STX-721 and STX-241 – into a new, as-yet-unnamed independent ...